Walking the path of treatable traits in interstitial lung diseases

Respiratory Research

Correspondence

Stefano Aliberti¹  Anna Stainer¹  Francesco Amati¹  Donato Lacedonia²  Christopher J. Ryerson³  Justin M. Oldham⁴  Andrea Gramegna⁵  Marco Mantero⁵  Francesco Blasi⁵  Luca Richeldi⁶  Paolo Spagnolo⁷  Nicola Sverzellati⁸ 

[1] Department of Biomedical Sciences, Humanitas University, Via Rita Levi Montalcini 4, 20072, Pieve Emanuele, Milan, Italy;IRCCS Humanitas Research Hospital, Respiratory Unit, Via Manzoni 56, 20089, Rozzano, Milan, Italy;Department of Medical and Occupational Sciences, Institute of Respiratory Disease, Università degli Studi di Foggia, Foggia, Italy;Department of Medicine, University of British Columbia and Centre for Heart Lung Innovation, St. Paul’s Hospital, Vancouver, Canada;Division of Pulmonary and Critical Care Medicine, Department of Internal Medicine, University of Michigan, Ann Arbor, MI, USA;Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Respiratory Unit and Cystic Fibrosis Adult Center, Milan, Italy;Department of Pathophysiology and Transplantation, Università degli Studi di Milano, Milan, Italy;Fondazione Policlinico A. Gemelli IRCCS, Università Cattolica del Sacro Cuore, Rome, Italy;Respiratory Disease Unit, Department of Cardiac, Thoracic, Vascular Sciences and Public Health, University of Padova, Padua, Italy;Unit of Scienze Radiologiche, Department of Medicine and Surgery, University of Parma, Parma, Italy;

关键词: Treatable traits;    Biomarkers;    Endotype;    Phenotype;    Interstitial lung diseases;    Personalized medicine;    Artificial intelligence;   

DOI  :  10.1186/s12931-023-02554-8

 received in 2023-08-25, accepted in 2023-10-05,  发布年份 2023

来源: Springer

【 摘 要 】

Interstitial lung diseases (ILDs) are complex and heterogeneous diseases. The use of traditional diagnostic classification in ILD can lead to suboptimal management, which is worsened by not considering the molecular pathways, biological complexity, and disease phenotypes. The identification of specific “treatable traits” in ILDs, which are clinically relevant and modifiable disease characteristics, may improve patient’s outcomes. Treatable traits in ILDs may be classified into four different domains (pulmonary, aetiological, comorbidities, and lifestyle), which will facilitate identification of related assessment tools, treatment options, and expected benefits. A multidisciplinary care team model is a potential way to implement a “treatable traits” strategy into clinical practice with the aim of improving patients’ outcomes. Multidisciplinary models of care, international registries, and the use of artificial intelligence may facilitate the implementation of the “treatable traits” approach into clinical practice. Prospective studies are needed to test potential therapies for a variety of treatable traits to further advance care of patients with ILD.

【 授权许可】

CC BY   
© BioMed Central Ltd., part of Springer Nature 2023

【 图 表 】

12951_2017_255_Article_IEq39.gif

Fig. 4